产品简要
公司名称 :
赛默飞世尔
其他品牌 :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
产品类型 :
抗体
产品名称 :
v-erb-b2成红细胞白血病病毒致瘤基因2(HER-2)重组兔单克隆抗体(SP3)
目录 :
MA1-39544
规格 :
1毫升
价格 :
美国1000.00
克隆性 :
重组
宿主 :
domestic rabbit
共轭标签 :
未共轭
克隆名称 :
SP3
反应物种 :
人类, 小鼠, 大鼠
应用 :
免疫印迹, 免疫组化, 免疫细胞化学, 免疫组化-石蜡切片
更多信息或购买 :
文章摘录数: 112
出版应用/物种/样本/稀释参考文献
  • 免疫组化-石蜡切片; 人类; 1:100; 图 2a
Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2018;172:373-386.e10 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1c
Dobosz M, Haupt U, Scheuer W. Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule. MAbs. 2017;9:140-153 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 1:200; 表 5
Liu Y, Wang K, Xing H, Zhai X, Wang L, Wang W. Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers. Oncol Lett. 2016;12:1240-1256 pubmed
  • 免疫组化-石蜡切片; 人类; 1:100; 表 1
Chung M, Lee J, Kim S, Suh Y, Choi H. Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer. Medicine (Baltimore). 2016;95:e3689 pubmed 出版商
  • 免疫组化; 人类; 1:200
Matsumoto H, Thike A, Li H, Yeong J, Koo S, Dent R, et al. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res Treat. 2016;156:237-47 pubmed 出版商
  • 免疫组化; 人类; ready to use
KapucuoÄŸlu N, Bozkurt K, BaÅŸpınar Å, Koçer M, EroÄŸlu H, Akdeniz R, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015;211:740-7 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 图 1f
Wang D, Pang Z, Clarke G, Nofech Mozes S, Liu K, Cheung A, et al. Ki-67 Membranous Staining: Biologically Relevant or an Artifact of Multiplexed Immunofluorescent Staining. Appl Immunohistochem Mol Morphol. 2016;24:447-52 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 1:200; 表 2
Cheung S, Boey Y, Koh V, Thike A, Lim J, Iqbal J, et al. Role of epithelial-mesenchymal transition markers in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152:489-98 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 1:200
Koh V, Lim J, Thike A, Cheok P, Thu M, Tan V, et al. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat. 2015;152:293-304 pubmed 出版商
  • 免疫组化; 人类; 1:100
de Deus Moura R, Carvalho F, Bacchi C. Breast cancer in very young women: Clinicopathological study of 149 patients ≤25 years old. Breast. 2015;24:461-7 pubmed 出版商
  • 免疫组化-石蜡切片; 人类
Nwafor C, Keshinro S. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience. Niger J Clin Pract. 2015;18:553-8 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 表 2
Savci Heijink C, Halfwerk H, Hooijer G, Horlings H, Wesseling J, van de Vijver M. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015;150:547-57 pubmed 出版商
  • 免疫组化; 人类; 1:200
Oon M, Thike A, Tan S, Tan P. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast. Breast Cancer Res Treat. 2015;150:31-41 pubmed 出版商
  • 免疫组化-石蜡切片; 人类
Tu J, Yu Y, Liu W, Chen S. Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med. 2015;9:17-24 pubmed
  • 免疫组化; 人类; 1:100
Carvalho F, Bacchi L, Pincerato K, van de Rijn M, Bacchi C. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health. 2014;14:102 pubmed 出版商
  • 免疫组化; 人类
Dean S, Perks C, Holly J, Bhoo Pathy N, Looi L, Mohammed N, et al. Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. Am J Clin Pathol. 2014;141:323-33 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 1:200
Jackson D, Atkinson J, Guevara C, Zhang C, Kery V, Moon S, et al. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS ONE. 2014;9:e83865 pubmed 出版商
  • 免疫组化; 人类; 1:100
Clarke G, Zubovits J, Shaikh K, Wang D, Dinn S, Corwin A, et al. A novel, automated technology for multiplex biomarker imaging and application to breast cancer. Histopathology. 2014;64:242-55 pubmed 出版商
  • 免疫组化; 人类; 1:50
Kuijpers C, Moelans C, van Slooten H, Horstman A, Hinrichs J, Al Janabi S, et al. Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer. PLoS ONE. 2013;8:e82018 pubmed 出版商
  • 免疫细胞化学; 人类
  • 免疫印迹; 人类
Galletti G, Sung M, Vahdat L, Shah M, Santana S, Altavilla G, et al. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip. 2014;14:147-56 pubmed 出版商
  • 免疫组化; 人类; 1:200
Gulbahce H, Vanderwerf S, Blair C, Sweeney C. Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer. Hum Pathol. 2014;45:78-84 pubmed 出版商
  • 免疫组化; 人类; 1:200
Gulbahce H, Sweeney C, Surowiecka M, Knapp D, Varghese L, Blair C. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors. Hum Pathol. 2013;44:2427-31 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 1:100; 图 2
Vlug E, van de Ven R, Vermeulen J, Bult P, van Diest P, Derksen P. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr). 2013;36:375-84 pubmed 出版商
  • 免疫组化; 人类; 1:500
Nunes C, Rocha R, Buzelin M, Balabram D, de Souza Foureaux F, Porto S, et al. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma. J Clin Pathol. 2013;66:946-50 pubmed 出版商
  • 免疫组化; 人类; 1:200
Do S, Kim K, Kim D, Chae S, Park Y, Park C, et al. Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas. J Breast Cancer. 2013;16:152-8 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 1:100; 表 1
Aguiar F, Mendes H, Cirqueira C, Bacchi C, Carvalho F. Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ. Clinics (Sao Paulo). 2013;68:638-43 pubmed 出版商
  • 免疫组化; 人类
Zhang X, Claerhout S, Prat A, Dobrolecki L, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73:4885-97 pubmed 出版商
  • 免疫组化; 人类
Postma E, Verkooijen H, van Diest P, Willems S, van den Bosch M, van Hillegersberg R. Discrepancy between routine and expert pathologists' assessment of non-palpable breast cancer and its impact on locoregional and systemic treatment. Eur J Pharmacol. 2013;717:31-5 pubmed 出版商
  • 免疫细胞化学; 人类; 1:40
van Hemel B, Suurmeijer A. Effective application of the methanol-based PreservCyt(™) fixative and the Cellient(™) automated cell block processor to diagnostic cytopathology, immunocytochemistry, and molecular biology. Diagn Cytopathol. 2013;41:734-41 pubmed 出版商
  • 免疫组化; 人类; 1:100
Limaye S, Posner M, Krane J, Fonfria M, Lorch J, Dillon D, et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013;18:294-300 pubmed 出版商
  • 免疫组化; 人类; 1:100
D Alfonso T, Liu Y, Chen Z, Chen Y, Cimino Mathews A, Shin S. SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients. J Clin Pathol. 2013;66:409-14 pubmed 出版商
  • 免疫组化; 人类; 1:100
Prins M, Ruurda J, van Diest P, van Hillegersberg R, ten Kate F. The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study. Ann Oncol. 2013;24:1290-7 pubmed 出版商
  • 免疫组化; 人类; 1:100
Vermeulen J, Kornegoor R, van der Wall E, van der Groep P, van Diest P. Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer. PLoS ONE. 2013;8:e53353 pubmed 出版商
  • 免疫细胞化学; 人类; 1:50
  • 免疫组化; 人类
Jambal P, Badtke M, Harrell J, Borges V, Post M, Sollender G, et al. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat. 2013;137:431-48 pubmed 出版商
  • 免疫组化; 人类
Rau K, Huang C, Chiu T, Chen Y, Lu C, Liu C, et al. Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. Exp Ther Med. 2012;4:231-236 pubmed
  • 免疫组化; 人类; 1:100
Kornegoor R, Verschuur Maes A, Buerger H, Hogenes M, de Bruin P, Oudejans J, et al. Immunophenotyping of male breast cancer. Histopathology. 2012;61:1145-55 pubmed 出版商
  • 免疫组化; 人类; 1:200
Iqbal J, Thike A, Cheok P, Tse G, Tan P. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer. Histopathology. 2012;61:652-9 pubmed 出版商
  • 免疫组化; 人类; 1:100
Vermeulen J, van Brussel A, van der Groep P, Morsink F, Bult P, van der Wall E, et al. Immunophenotyping invasive breast cancer: paving the road for molecular imaging. BMC Cancer. 2012;12:240 pubmed 出版商
  • 免疫组化; 人类
Dekker T, Borg S, Hooijer G, Meijer S, Wesseling J, Boers J, et al. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res. 2012;14:R93 pubmed
  • 免疫组化; 人类; 1:100
Vermeulen J, van de Ven R, Ercan C, van der Groep P, van der Wall E, Bult P, et al. Nuclear Kaiso expression is associated with high grade and triple-negative invasive breast cancer. PLoS ONE. 2012;7:e37864 pubmed 出版商
  • 免疫组化; 人类; 1:100
Hoefnagel L, Moelans C, Meijer S, van Slooten H, Wesseling P, Wesseling J, et al. Prognostic value of estrogen receptor ? and progesterone receptor conversion in distant breast cancer metastases. Cancer. 2012;118:4929-35 pubmed 出版商
  • 免疫组化; 人类; 1:100
Sanli Y, Kuyumcu S, Ozkan Z, Işık G, Karanlik H, Guzelbey B, et al. Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med. 2012;26:345-50 pubmed 出版商
  • 免疫组化; 人类; 1:100
Schillaci R, Guzman P, Cayrol F, Beguelin W, Díaz Flaqué M, Proietti C, et al. Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer. 2012;12:74 pubmed 出版商
  • 免疫组化; 人类; 1:100
Kornegoor R, Verschuur Maes A, Buerger H, van Diest P. The 3-layered ductal epithelium in gynecomastia. Am J Surg Pathol. 2012;36:762-8 pubmed 出版商
  • 免疫组化; 人类; 1:100
Belt E, Brosens R, Delis van Diemen P, Bril H, Tijssen M, van Essen D, et al. Cell cycle proteins predict recurrence in stage II and III colon cancer. Ann Surg Oncol. 2012;19 Suppl 3:S682-92 pubmed 出版商
  • 免疫组化; 人类
MacFarlane R, Seal M, Speers C, Woods R, Masoudi H, Aparicio S, et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist. 2012;17:172-8 pubmed 出版商
  • 免疫组化; 大鼠; 1:200
Einbond L, Soffritti M, Degli Esposti D, Tibaldi E, Lauriola M, Bua L, et al. Chemopreventive potential of black cohosh on breast cancer in Sprague-Dawley rats. Anticancer Res. 2012;32:21-30 pubmed
  • 免疫印迹; 人类
Zheng G, Xiong Y, Yi S, Zhang W, Peng B, Zhang Q, et al. 14-3-3? regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation. FEBS Lett. 2012;586:163-8 pubmed 出版商
  • 免疫组化; 人类; 1:400
Reisenbichler E, Horton D, Rasco M, Andea A, Hameed O. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section. Am J Clin Pathol. 2012;137:102-10 pubmed 出版商
  • 免疫组化; 人类; 1:100
Naushad S, Pavani A, Rupasree Y, Divyya S, Deepti S, Digumarti R, et al. Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer. Mol Carcinog. 2012;51 Suppl 1:E32-41 pubmed 出版商
  • 免疫组化; 人类
Liu W, Zhong S, Chen J, Yu Y. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. J Clin Gastroenterol. 2012;46:e31-7 pubmed 出版商
  • 免疫组化; 人类; 1:100
Lee D, Kim S, Suh Y, Kim S, Kim H, Shim B. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy. Jpn J Clin Oncol. 2011;41:854-66 pubmed 出版商
  • 免疫组化; 人类; 1:100
  • 免疫印迹; 人类
Jan C, Yu C, Hung M, Harn H, Nieh S, Lee H, et al. Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients. J Pathol. 2011;225:424-37 pubmed 出版商
  • 免疫组化; 大鼠; 1:3000
  • 免疫组化; 人类
Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011;13:R46 pubmed 出版商
  • 免疫组化; 人类
Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011;306:171-9 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 1:200
Teng Y, Tan W, Thike A, Cheok P, Tse G, Wong N, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011;13:R35 pubmed 出版商
  • 免疫组化; 人类; 1:80
Martins D, Sousa B, Lopes N, Gomes M, Veronese L, Albergaria A, et al. Molecular phenotypes of matched in situ and invasive components of breast carcinomas. Hum Pathol. 2011;42:1438-46 pubmed 出版商
  • 免疫组化; 人类; 1:200
Allison K, Kandalaft P, Sitlani C, Dintzis S, Gown A. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?. Breast Cancer Res Treat. 2012;131:413-24 pubmed 出版商
  • 免疫组化; 人类; 1:100
Heerma van Voss M, van der Groep P, Bart J, van der Wall E, van Diest P. Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cell Oncol (Dordr). 2011;34:3-10 pubmed 出版商
  • 免疫组化; 人类; 1:350
Bong P, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Emran N, et al. Expression and mutational analysis of GATA3 in Malaysian breast carcinomas. Malays J Pathol. 2010;32:117-22 pubmed
  • 免疫组化; 人类
Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskin Y, Yigit S, et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci. 2011;8:148-55 pubmed
  • 免疫组化; 人类
Boers J, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2011;58:383-94 pubmed 出版商
  • 免疫组化; 人类; 1:200
Ahmed S, Iqbal J, Thike A, Lim A, Lim T, Tien S, et al. HER2/neu revisited: quality and interpretive issues. J Clin Pathol. 2011;64:120-4 pubmed 出版商
  • 免疫组化; 人类; 1:25
Joosse S, Brandwijk K, Mulder L, Wesseling J, Hannemann J, Nederlof P. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer. 2011;50:71-81 pubmed 出版商
  • 免疫组化; 人类
Rhodes A, Sarson J, Assam E, Dean S, Cribb E, Parker A. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am J Clin Pathol. 2010;134:621-32 pubmed 出版商
  • 免疫组化; 人类; 1:200
Lwin Z, Guo C, Salim A, Yip G, Chew F, Nan J, et al. Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod Pathol. 2010;23:1559-66 pubmed 出版商
  • 免疫组化; 人类; 1:25
Holstege H, van Beers E, Velds A, Liu X, Joosse S, Klarenbeek S, et al. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. BMC Cancer. 2010;10:455 pubmed 出版商
  • 免疫组化; 人类
Tan Y, Han S, Lu Y, Yip C, Sunpaweravong P, Jeong J, et al. The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey. Cancer. 2010;116:5348-57 pubmed 出版商
  • 免疫组化; 人类; 1:25
Joosse S, Brandwijk K, Devilee P, Wesseling J, Hogervorst F, Verhoef S, et al. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Breast Cancer Res Treat. 2012;132:379-89 pubmed 出版商
  • 免疫组化; 人类
Lee C, Tannock I. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer. 2010;10:255 pubmed 出版商
  • 免疫组化; 人类; 1:200
Tan M, Wong C, Tan H, Yang X, Ditlev J, Matsuda D, et al. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer. 2010;10:196 pubmed 出版商
  • 免疫印迹; 人类
Shi M, Liu D, Duan H, Qian L, Wang L, Niu L, et al. The ?2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat. 2011;125:351-62 pubmed 出版商
  • 免疫组化; 人类; 1:50
Munjal K, Ambaye A, Evans M, Mitchell J, Nandedkar S, Cooper K. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev. 2009;10:773-8 pubmed
  • 免疫组化; 人类; 1:80
Lopes N, Sousa B, Vieira D, Milanezi F, Schmitt F. Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology. 2009;55:594-9 pubmed 出版商
  • 免疫组化; 人类; 1:200
Thike A, Cheok P, Jara Lazaro A, Tan B, Tan P, Tan P. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010;23:123-33 pubmed 出版商
  • 免疫组化; 人类; 1:100
Wang C, Iakovlev V, Wong V, Leung S, Warren K, Iakovleva G, et al. Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study. Genes Chromosomes Cancer. 2009;48:1091-101 pubmed 出版商
  • 免疫细胞化学; 小鼠; 1:50
Behbod F, Kittrell F, LaMarca H, Edwards D, Kerbawy S, Heestand J, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009;11:R66 pubmed 出版商
  • 免疫组化; 人类
Freedman O, Amir E, Hanna W, Kahn H, O Malley F, Dranitsaris G, et al. A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2010;119:155-61 pubmed 出版商
  • 免疫组化; 人类; 1:50
Sassen A, Diermeier Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, et al. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res. 2009;11:R50 pubmed 出版商
  • 免疫组化; 人类; 1:3000
Bueno de Mesquita J, Nuyten D, Wesseling J, VAN Tinteren H, Linn S, van de Vijver M. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol. 2010;21:40-7 pubmed 出版商
  • 免疫组化; 人类; 1:200
Nofech Mozes S, Hanna W. Toker cells revisited. Breast J. 2009;15:394-8 pubmed 出版商
  • 免疫组化; 人类
Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W. The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer. 2009;9:226 pubmed 出版商
  • 免疫组化; 人类; 1:300
Rocha R, Nunes C, Sanches F, Rocha G, Oliveira F, Reis Filho J, et al. Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer. Rev Assoc Med Bras (1992). 2009;55:163-8 pubmed
  • 免疫组化; 人类; 1:80
Dufloth R, Alves J, Martins D, Vieira D, Chikota H, Zeferino L, et al. Cytological criteria to predict basal phenotype of breast carcinomas. Diagn Cytopathol. 2009;37:809-14 pubmed 出版商
  • 免疫组化; 人类
  • 免疫印迹; 人类; 1:2000
Yu G, Chen Y, Wang J. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol. 2009;135:1331-9 pubmed 出版商
  • 免疫组化; 人类; 1:100
Rosa F, Silveira S, Silveira C, Bérgamo N, Neto F, Domingues M, et al. Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer. 2009;9:90 pubmed 出版商
  • 免疫组化; 人类; 1:100
Boone J, van Hillegersberg R, Offerhaus G, van Diest P, Borel Rinkes I, ten Kate F. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus. 2009;22:496-504 pubmed 出版商
  • 免疫组化; 人类; 1:800
Tezel G, Uner A, Yildiz I, Guler G, Takahashi M. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression. Pathol Res Pract. 2009;205:403-8 pubmed 出版商
  • 免疫组化; 人类
Sun L, Wang D, Zubovits J, Yaffe M, Clarke G. An improved processing method for breast whole-mount serial sections for three-dimensional histopathology imaging. Am J Clin Pathol. 2009;131:383-92 pubmed 出版商
  • 免疫组化; 人类; 1:100
Hanley K, Siddiqui M, Lawson D, Cohen C, Nassar A. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis. Diagn Cytopathol. 2009;37:251-7 pubmed 出版商
  • 免疫组化; 人类; 1:100
Liu S, Chia S, Mehl E, Leung S, Rajput A, Cheang M, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat. 2010;119:53-61 pubmed 出版商
  • 免疫组化; 人类; 1:100
Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown A, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26:5697-704 pubmed 出版商
  • 免疫组化; 人类; 1:50
van Dekken H, Hop W, Tilanus H, Haringsma J, van der Valk H, Wink J, et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol. 2008;130:745-53 pubmed 出版商
  • 免疫组化; 人类; 1:25
Joosse S, van Beers E, Tielen I, Horlings H, Peterse J, Hoogerbrugge N, et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat. 2009;116:479-89 pubmed 出版商
  • 免疫组化-石蜡切片; 人类; 1:400; 表 3
  • 免疫组化; 人类; 1:400
Kim T, Huh J, Lee S, Kang H, Kim G, An H. Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease. Histopathology. 2008;53:48-55 pubmed 出版商
  • 免疫组化; 人类
Jensen M, Schoepfer J, Radimerski T, Massey A, Guy C, Brueggen J, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 2008;10:R33 pubmed 出版商
  • 免疫组化; 人类; 1:100
Cheang M, Voduc D, Bajdik C, Leung S, McKinney S, Chia S, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-76 pubmed 出版商
  • 免疫组化; 人类
Tan B, Tan L, Yu K, Tan P, Lee M, Sii L, et al. Clinical validation of a customized multiple signature microarray for breast cancer. Clin Cancer Res. 2008;14:461-9 pubmed 出版商
  • 免疫组化; 人类; 1:100
Crabb S, Bajdik C, Leung S, Speers C, Kennecke H, Huntsman D, et al. Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res. 2008;10:R6 pubmed 出版商
  • 免疫组化; 人类; 1:100
Wong S, Chan J, Lo E, Chan A, Wong M, Chan C, et al. The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry. Arch Pathol Lab Med. 2007;131:1047-55 pubmed
  • 免疫组化; 人类; 1:200
Selvarajan S, Sii L, Lee A, Yip G, Bay B, Tan M, et al. Parafibromin expression in breast cancer: a novel marker for prognostication?. J Clin Pathol. 2008;61:64-7 pubmed
  • 免疫组化; 人类; 1:100
Rajput A, Turbin D, Cheang M, Voduc D, Leung S, Gelmon K, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2008;107:249-57 pubmed
  • 免疫组化; 人类
Nadasi E, Anga B, Sandor J, Megyesi J, Kelemen D, Mottolese M, et al. Prognostic factors in Hungarian breast cancer patients. Anticancer Res. 2007;27:279-82 pubmed
  • 免疫组化; 人类; 1:800
Short S, Yoder B, Tarr S, Prescott N, Laniauskas S, Coleman K, et al. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. Breast J. 2007;13:130-9 pubmed
  • 免疫组化; 人类; 1:200
Ho B, Tan H, Lee V, Tan P. Preoperative and intraoperative diagnosis of low-grade adenosquamous carcinoma of the breast: potential diagnostic pitfalls. Histopathology. 2006;49:603-11 pubmed
  • 免疫组化; 人类; 1:80
Ricardo S, Milanezi F, Carvalho S, Leitão D, Schmitt F. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol. 2007;60:1001-5 pubmed
Arnli M, Winther T, Lydersen S, Torp S. Prognostic value of ErbB2/HER2 in human meningiomas. PLoS ONE. 2018;13:e0205846 pubmed 出版商
Ni J, Ramkissoon S, Xie S, Goel S, Stover D, Guo H, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016;22:723-6 pubmed 出版商
Vermeulen J, van der Wall E, Witkamp A, van Diest P. Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging. Cell Oncol (Dordr). 2013;36:333-40 pubmed 出版商
Benatar T, Yang W, Amemiya Y, Evdokimova V, Kahn H, Holloway C, et al. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res Treat. 2012;133:563-73 pubmed 出版商
Lee D, Kim S, Kim S, Suh Y, Kim H, Shim B. Prognostic significance of breast cancer subtype and p53 overexpression in patients with locally advanced or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapy. Int J Clin Oncol. 2012;17:447-55 pubmed 出版商
Subramaniam M, Ng S, Seah S, Anuar D, Soong R, Lee V. Molecular characterization of dedifferentiated mucoepidermoid carcinoma of the trachea using laser microdissection-based TP53 mutation analysis. Histopathology. 2009;55:472-5 pubmed 出版商
图像
图像 1 :
赛默飞世尔 MA1-39544 图像 1
产品信息
产品类型 :
抗体
产品名称 :
v-erb-b2成红细胞白血病病毒致瘤基因2(HER-2)重组兔单克隆抗体(SP3)
目录# :
MA1-39544
规格 :
1毫升
价格 :
美国1000.00
克隆性 :
重组单克隆
纯度 :
蛋白质A
宿主 :
反应物种 :
人类
应用 :
免疫组化(石蜡): 1:100
物种 :
人类
克隆 :
SP3
抗体亚型 :
IgG
储存 :
-20° C, 避免反复冷冻/解冻
描述 :
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
免疫原 :
Recombinant protein encoding extracellular domain of human c-erbB2
格式 :
液体
应用w/稀释 :
免疫组化(石蜡): 1:100
别名 :
avian erythroblastosis oncogene B 2; Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog); CD antigen CD340; CD340; c-erb B2/neu protein; c-erbB2; C-erbB-2; c-neu; epidermal growth factor receptor-related protein; erbb 2; ERBB2; erb-b2; Erbb-2; ErbB2 (pTyr1139); ErbB2 (pY1139); ErbB2 phospho Y1139; erb-b2 receptor tyrosine kinase 2; her 2; HER2; HER-2; HER-2/neu; herstatin; human epidermal growth factor receptor 2; Kiaa3023; metas; Metastatic lymph node gene 19 protein; mKIAA3023; MLN 19; MLN19; NEU; Neu oncogene; NEU proto-oncogene; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; p185erbB2; p185neu; phospho ErbB2; proto-oncogene c-ErbB-2; Proto-oncogene Neu; receptor tyrosine-protein kinase erbB-2; TKR1; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
更多信息或购买 :
公司信息
赛默飞世尔
上海浦东新金桥路27号7号楼
analyze.cn@thermofisher.com
http://www.thermo.com.cn
1084193588
公司总部: 美国